EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/ II Clinical Trial

Yu Xue, Ning Zhang, Jiankang Hu, Wei Gou, Lin Chen, Lin Tang, Yanlin Li iD, Lihui Ma, Zhenchun Zhang, Meirong Li, Lingli Dong, Xinwang Duan und 14 weitere

International Journal of Rheumatic Diseases · 2026-07 · 29 (7)

DOI: 10.1111/1756-185x.70785 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 24.07.2026. Verfasst von Yu Xue und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China. Hauptthemen laut MEDLINE: Gout, Gout Suppressants. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This Phase Ib/II study aimed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Firsekibart in the treatment of gout flares.

Methods

Phase Ib part utilized an open‐label, single‐dose, dose‐escalation design. Patients were enrolled and received a single subcutaneous injection of Firsekibart at a dose of 50, 100, or 195 mg. Phase II part was a multicenter, randomized, double‐blind, parallel, positive‐controlled study. Patients were assigned to receive either Firsekibart (100 or 195 mg) or Diprospan.

Results

As of June 9, 2022, a total of 120 patients (Phase Ib N = 29, Phase II N = 91) received the study drugs. In Phase Ib, Firsekibart demonstrated dose‐dependent efficacy. Firsekibart 50 mg treatment provided less pain relief compared to the 100 mg and 195 mg. In Phase II, the visual analogue scale (VAS) score decreased by 5.51 ± 1.56, 4.72 ± 1.56 and 4.94 ± 2.44 cm after 72 h in Firsekibart 195 mg, 100 mg and Diprospan groups, respectively. Firsekibart 195 mg treatment showed a more effective pain relief trend. The pharmacokinetic (PK) profile of serum Firsekibart exhibits typical characteristics of monoclonal antibodies, featuring slow absorption (median T max approximately 5.9–6.9 days), limited distribution (distributed volume approximately 8.0–12.1 L) and slow elimination (clearance approximately 9.2–11.5 mL/h). Safety of Firsekibart was favorable and comparable across doses and relative to Diprospan.

Conclusion

A single subcutaneous injection of Firsekibart is safe and well tolerated in the treatment of gout flares. It provides dose‐dependent pain relief with favorable pharmacokinetic properties and potential for reducing the risk of gout flare recurrence. Trail Registration Trial Registration: ClinicalTrials.gov NCT05328531

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutGout SuppressantsHumansFemaleMaleDouble-Blind MethodInjections, SubcutaneousMiddle AgedTreatment OutcomeDose-Response Relationship, DrugAdultAged

Stichwörter der Autor:innen

Firsekibartefficacygoutinterleukin 1βpharmacokineticsphase Ib/II trialsafety

Substanzen

Gout Suppressants

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China.
  • Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Rheumatology and Immunology, Pingxiang People's Hospital, Pingxiang, Jiangxi, China.
  • Department of Rheumatology and Immunology, Hebei Petro China Central Hospital, Langfang, Hebei, China.
  • Department of Rheumatology and Immunology, Jilin Province People's Hospital, Changchun, Jilin, China.
  • Department of Rheumatology and Immunology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China.

ORCID-Profile: Yanlin Li, Liyan Miao, Jing Zhang, Hejian Zou

Zitieren

APA

Xue, Y., Zhang, N., Hu, J., Gou, W., Chen, L., Tang, L., Li, Y., Ma, L., Zhang, Z., Li, M., Dong, L., Duan, X., Qin, L., Yuan, G., Miao, L., Wu, J., Qian, L., Hu, W., Tan, W., …, & Zou, H. (2026). Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/ II Clinical Trial. International Journal of Rheumatic Diseases, 29(7). https://doi.org/10.1111/1756-185x.70785

Vancouver

Xue Y, Zhang N, Hu J, Gou W, Chen L, Tang L, et al. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/ II Clinical Trial. International Journal of Rheumatic Diseases. 2026;29(7). doi:10.1111/1756-185x.70785

BibTeX
@article{Xue2026,
  author = {Xue, Yu and Zhang, Ning and Hu, Jiankang and Gou, Wei and Chen, Lin and Tang, Lin and Li, Yanlin and Ma, Lihui and Zhang, Zhenchun and Li, Meirong and Dong, Lingli and Duan, Xinwang and Qin, Li and Yuan, Guohua and Miao, Liyan and Wu, Jian and Qian, Long and Hu, Wei and Tan, Wenfeng and Li, Jingyang and Da, Zhanyun and Xu, Qian and Chen, Chunxia and Luo, Tianhong and Zhang, Jing and Zou, Hejian},
  title = {Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/ II Clinical Trial},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  volume = {29},
  number = {7},
  doi = {10.1111/1756-185x.70785}
}
Kostenlos starten →